Martin Posch

Martin Posch

Auto-generated profile, based on publicly available information

Martin Posch

Center for Medical Data Science Medical University of Vienna Vienna Austria

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2008 in Journal of Rehabilitation Medicine
Verified
Journal Article
Open access
TPT Paternostro-Sluga
T Paternostro-Sluga
MGM Grim-Stieger
M Grim-Stieger
MPM Posch
M Posch
OSO Schuhfried
O Schuhfried
GVG Vacariu
G Vacariu
VFV Fialka-Moser
V Fialka-Moser
Journal of Rehabilitation Medicine is an international peer-review journal published in English, with at least 10 issues published per year.

2 December 2008 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
FBFrank Bretz
Frank Bretz
WMWilli Maurer
Willi Maurer
WBWerner Brannath
Werner Brannath
MPMartin Posch
Martin Posch

1 September 2014 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
DBD.M. Baron
D.M. Baron
HHH. Hochrieser
H. Hochrieser
MPM. Posch
M. Posch
BMB. Metnitz
B. Metnitz
ARA. Rhodes
A. Rhodes
PMP. Metnitz
P. Metnitz
Retrospective studies suggest that preoperative anaemia is associated with poor outcomes after surgery. The objective of this study was to describe mortality rates and patterns of intensive care resource use for patients with anaemia undergoing non-cardiac and non-neurological in-patient surgery. We performed a secondary analysis of a large prospective study describing perioperative care and survival in 28 European nations. Patients at least 16 yr old undergoing in-patient surgery during a 7 day period were included in the study. Data were collected for in-hospital mortality, duration of hospital stay, admission to intensive care, and intensive care resource use. Multivariable logistic regression analysis was performed to understand the effects of preoperative haemoglobin (Hb) levels on in-hospital mortality. We included 39 309 patients in the analysis. Preoperative anaemia had a high prevalence in both men and women (31.1% and 26.5%, respectively). Multivariate analysis showed that patients with severe [odds ratio 2.82 (95% confidence interval 2.06-3.85)] or moderate [1.99 (1.67-2.37)] anaemia had higher in-hospital mortality than those with normal preoperative Hb concentrations. Furthermore, hospital length of stay (P<0.001) and postoperative admission to intensive care (P<0.001) were greater in patients with anaemia than in those with normal Hb concentrations. Anaemia is common among non-cardiac and non-neurological surgical patients, and is associated with poor clinical outcome and increased healthcare resource use. NCT01203605 (ClinicalTrials.gov).

14 December 2017 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
FEFarsad Eskandary
Farsad Eskandary
HRHeinz Regele
Heinz Regele
LBLukas Baumann
Lukas Baumann
GBGregor Bond
Gregor Bond
NKNicolas Kozakowski
Nicolas Kozakowski
GBGeorg A. Böhmig
Georg A. Böhmig
Late antibody-mediated rejection (ABMR) is a leading cause of kidney allograft failure. Uncontrolled studies have suggested efficacy of the proteasome inhibitor bortezomib, but no systematic trial has been undertaken to support its use in ABMR. In this randomized, placebo-controlled trial (the Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection [BORTEJECT] Trial), we investigated whether two cycles of bortezomib (each cycle: 1.3 mg/m2 intravenously on days 1, 4, 8, and 11) prevent GFR decline by halting the progression of late donor-specific antibody (DSA)–positive ABMR. Forty-four DSA-positive kidney transplant recipients with characteristic ABMR morphology (median time after transplant, 5.0 years; pretransplant DSA documented in 19 recipients), who were identified on cross-sectional screening of 741 patients, were randomly assigned to receive bortezomib (n=21) or placebo (n=23). The 0.5-ml/min per 1.73 m2 per year (95% confidence interval, −4.8 to 5.8) difference detected between bortezomib and placebo in eGFR slope (primary end point) was not significant (P=0.86). We detected no significant differences between bortezomib- and placebo-treated groups in median measured GFR at 24 months (33 versus 42 ml/min per 1.73 m2; P=0.31), 2-year graft survival (81% versus 96%; P=0.12), urinary protein concentration, DSA levels, or morphologic or molecular rejection phenotypes in 24-month follow-up biopsy specimens. Bortezomib, however, associated with gastrointestinal and hematologic toxicity. In conclusion, our trial failed to show that bortezomib prevents GFR loss, improves histologic or molecular disease features, or reduces DSA, despite significant toxicity. Our results reinforce the need for systematic trials to dissect the efficiency and safety of new treatments for late ABMR.

13 March 2009 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
FBFrank Bretz
Frank Bretz
FKFranz Koenig
Franz Koenig
WBWerner Brannath
Werner Brannath
EGEkkehard Glimm
Ekkehard Glimm
MPMartin Posch
Martin Posch

30 November 2005 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
MPMartin Posch
Martin Posch
FKFranz Koenig
Franz Koenig
MBMichael Branson
Michael Branson
WBWerner Brannath
Werner Brannath
CDCornelia Dunger‐Baldauf
Cornelia Dunger‐Baldauf
PBPeter Bauer
Peter Bauer